Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE COMPOUND 65 versus Q GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE COMPOUND 65 versus Q GESIC.
PROPOXYPHENE COMPOUND 65 vs Q-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is an opioid analgesic that binds to mu-opioid receptors in the central nervous system, resulting in inhibition of ascending pain pathways and alteration of pain perception. Acetaminophen component inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
Adults: 1 capsule (65 mg propoxyphene HCl + 650 mg acetaminophen) orally every 4 hours as needed; maximum 6 capsules per day.
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
The terminal elimination half-life of propoxyphene is approximately 8-24 hours (mean 12 hours) in healthy adults. The half-life of its active metabolite, norpropoxyphene, is 30-36 hours, leading to prolonged effects and potential accumulation with repeated dosing, especially in renal impairment.
Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia.
Renal excretion of propoxyphene and its metabolites accounts for approximately 70-90% of an administered dose, with less than 5% excreted as unchanged drug. The remainder is eliminated via bile and feces. Minor amounts are excreted in breast milk.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination